Research Assistant Professor
- ST527
- +852 2766 4202
- kim07.li@polyu.edu.hk
- Traditional Chinese Medicine
ORCID ID
SCOPUS IDBiography
Dr Li Jingjing Kim obtained his bachelor’s and master’s degrees in Chinese medicinal science from the Southwest Jiaotong University (SWJTU) and the University of Macau (UM), respectively. He received his PhD from the Department of Pharmacology and Pharmacy, The University of Hong Kong, in 2020. Before joining PolyU, he received a postdoctoral fellowship at Li Ka Shing Faculty of Medicine, The University of Hong Kong between 2020 and 2021.
Dr Li is interested in using different cells and animal models to study the underlying pathological mechanisms of angiogenesis in different diseases, such as ischemic stroke, Parkinson’s disease, Alzheimer’s disease and cancers. He is also interested in identifying the pharmacological and therapeutic properties of novel constituents derived from Traditional Chinese Medicine (TCM), particularly those that can be used to regulate angiogenesis in the above-mentioned diseases. During his PhD study and postdoctoral training, Dr Li has discovered several promising bioactive compounds from TCM, which could be used as complementary and alternative medicine for the treatment of cardiovascular diseases, neurodegenerative diseases and cancers. He has so far published more than twenty scientific papers in top-ranked peer-reviewed journals in the fields of pharmacology as well as integrative and complementary medicine.
Dr Li is currently a member of the young editorial board of the journal Military Medical Research and a review editor of several other scientific journals, including Frontiers in Pharmacology, Phytomedicine, Chinese Medicine, Biochemical Pharmacology, and Chinese Journal of Natural Medicines. His current research projects focus on investigating the role of vascular abnormality in the pathological process of neurodegenerative diseases (e.g. Parkinson’s disease and Alzheimer’s disease), as well as developing effective strategies (e.g. vascular normalization therapy) for the treatment of neurodegenerative diseases and cancers.
Education and Academic Qualifications
- Bachelor of Science, Southwest Jiaotong University
- Master of Science in Chinese Medicinal Science, University of Macau
- Doctor of Philosophy, The University of Hong Kong
Research Interests
Research Output
- Wu YH, Li JJ, Zhong XM, Shi JF, Cheng YF, He CL, Li JX, Zou L, Fu CM, Chen MW, Zhang JM, & Gao HL. A pH-sensitive supramolecular nanosystem with chlorin e6 and triptolide co-delivery for chemo-photodynamic combination therapy. Asian Journal of PharmaceuticalSciences (in press). (Co-first author)
- Liu ZY, Wu XP, Dai K, Li RK, Zhang JM, Sheng DK, Lee SMY, Leung GPH, Zhou GC, & Li JJ (2022). The new andrographolide derivative AGS-30 induces apoptosis in human colon cancer cells by activating a ROS-dependent JNK signalling pathway. Phytomedicine, 94: 153824. (Corresponding author)
- Li JJ, Li RK, Wu XP, Hoo RLC, Lee SMY, Cheung TMY, Ho BSY, & Leung GPH (2021). Amauroderma rugosum protects PC12 cells against 6-OHDA-induced neurotoxicity through antioxidant and anti-apoptotic effects. Oxidative Medicine and Cellular Longevity, 2021: 6683270.
- Shi JF, Li JJ, Li JX, Li RK, Wu XP, Gao F, Zou L, Mak WWS, Fu CM, Zhang JM*, & Leung GPH* (2021). Synergistic breast cancer suppression efficacy of doxorubicin by combination with glycyrrhetinic acid as an angiogenesis inhibitor. Phytomedicine, 81: 153408. (Co-first and corresponding author)
- Luo YY, Li JJ, Hu YC, Gao F, Leung GPH, Geng FN, Fu CM, & Zhang JM (2020). Injectable thermoresponsive nano-hydrogel loading triptolide for the anti-breast cancer enhancement via localized treatment based on “Two Strikes” effects. Acta Pharmaceutica Sinica B, 10(11): 2227-2245. (Co-first author)
- Li JJ, Li F, Tang F, Zhang JM, Li RK, Sheng DK, Lee SMY, Zhou GC, & Leung GPH (2020). AGS-30, an andrographolide derivative, suppresses tumor angiogenesis and growth in vitro and in vivo. Biochemical Pharmacology, 171: 113694.
- Li JJ, Tang F, Li RK, Chen ZJ, Lee SMY, Fu CM, Zhang JM, & Leung GPH (2020). Dietary compound glycyrrhetinic acid suppresses tumor angiogenesis and growth by modulating anti-angiogenic and pro-apoptotic pathways in vitro and in vivo. Journal of Nutritional Biochemistry, 77: 108268.
- Li JJ, Wu YH, Wang D, Zou L, Fu CM, Zhang JM, & Leung GPH (2019). Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects. Pharmacological Research, 146: 104313.
- Li JJ, Zhang JM, Zou L, Lee SMY, Yang C, Seto SW, & Leung GPH (2017). Pro-angiogenic effects of Ilexsaponin A1 on human umbilical vein endothelial cells in vitro and zebrafish in vivo. Phytomedicine, 36: 229-237.
- Zhang JM, Li JJ, Shi Z, Yang Y, Xie X, Lee SMY, Wang YT, Leong KW, & Chen MW (2017). pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and antiangiogenic activities. Acta Biomaterialia, 58: 349-364. (Co-first author)
